Primary efficacy endpoint analysis of the CARIN trial: Capecitabine (Cap) and bevacizumab (Bev) with or without vinorelbine (Vin) in first line metastatic breast cancer (MBC).

Welt, A., Lerchenmüller, C., Decker, T., Marschner, N., Salat, C., Hegewisch-Becker, S., 2013.

Cancer Res 73 (24 Suppl)(P3-13-01). doi:10.1158/0008-5472.SABCS13-P3-13-01

Studie: CARIN; Indikation: Mammakarzinom; Jahr: 2013; Veranstaltung: SABCS; Journal: Cancer Research

iOMEDICO AG
Hanferstraße 28
79108 Freiburg

Tel: 0761 - 15 242 0
E-Mail: info@iomedico.com